Articles tagged with Prostate Cancer
A study of over 2,700 men with localized prostate cancer found that initial treatment choice didn't affect depression or emotional well-being. However, factors such as age, overall health, and initial depressive symptoms were linked to declines in mental health outcomes.
Researchers at Toyohashi University of Technology developed a microchip capable of detecting ultra-low concentrations of prostate cancer antigens using flexible nanosheets. The chip's lower detection limit is comparable to that of large testing devices, enabling fast and accurate diagnosis.
A study of nearly 40,000 Medicare beneficiaries found racial disparities in the use of MRI among Black and white patients with new prostate cancer diagnoses. The study identified factors such as insurance coverage, socioeconomic status, and geographic location that contribute to these disparities.
Cedars-Sinai investigators discover that inhibiting RIPK2 function with drugs or CRISPR/Cas9 reduces prostate cancer metastasis in mice, offering new hope for advanced prostate cancer treatment. Targeting this protein could extend patients' lives by several years.
A phase 3 trial demonstrates that adding darolutamide to standard therapy prolongs the survival of men with metastatic, hormone-sensitive prostate cancer. The treatment also delays disease progression and reduces need for additional therapies.
A supervised exercise program can reduce anxiety and fear of cancer progression in men undergoing active surveillance for prostate cancer. The study found significant improvements in mental and physical health benefits, including a reduction in prostate cancer-related anxiety and fear of progression.
Researchers developed patient surrogates to evaluate potential prostate cancer treatments, identifying genes that could be targeted with drugs. The models predicted synergistic effects of treatments and identified promising drug combinations.
Researchers have identified an antibody drug that significantly improves survival rates in pet dogs with advanced prostate cancer. By targeting regulatory T cells, the treatment may offer a new hope for patients with this devastating disease.
A recent study reveals that Black and Latinx men are severely underrepresented in online prostate cancer resources. The study found that only 9% of people depicted in online content were Black or Latinx, highlighting the need for greater representation and diversity in health education.
A novel blood test, Stockholm3, in combination with MRI reduces overdiagnosis of low-risk cancers by 60% and unnecessary biopsies by 9%. This cost-effective approach is recommended for Sweden's organized prostate cancer testing (OPT) pilot projects.
A new analysis links genetic variants associated with high blood levels of lipoprotein A to a higher risk of prostate cancer, including advanced or early-age-onset cases. The study found no significant associations for other blood lipids.
A recent study has found that faulty versions of the BRCA1 and BRCA2 genes are associated with an increased risk of developing prostate and pancreatic cancers in men. The study analyzed data from over 3,200 families and estimated that men who carry a BRCA2 mutation have a 27% risk of developing prostate cancer by age 80.
A new study confirms the accuracy of the European Association of Urology (EAU) risk classification system for prostate cancer patients, using PSMA PET imaging to identify subgroups with varying disease risks. High-risk groups showed higher metastatic disease rates, while low-risk groups had undetectable or distant metastases.
A UCLA-led meta-analysis of individual patient data from three cohorts found that patients receiving high-dose external beam radiation therapy alone may benefit from longer androgen deprivation therapy (ADT) durations, while those with external beam radiation therapy and brachytherapy boost may be optimally managed with shorter ADT. Th...
A new meta-analysis of randomized clinical trials found that adding androgen deprivation therapy (ADT) to definitive radiotherapy prevents one cancer from metastasizing for every 10 to 15 men treated. Prolonging adjuvant ADT also showed significant benefits, while neoadjuvant ADT was not effective beyond two months.
A newly identified molecular signal can spot aggressive tumor cells in early prostate cancers, allowing for targeted treatment. Researchers at Duke University Medical Center have developed a test to guide treatment based on this genomic signature.
A recent analysis of 7.8 million VA patients found significant disparities in localized and metastatic prostate cancer incidence between African Americans and whites. The study highlights the need for targeted interventions to address racial gaps in prostate cancer care.
A recent study by Moffitt researchers found that African American veterans had a significantly higher incidence of prostate cancer compared to European American men. The study also revealed that timely treatment and clear documentation are crucial in reducing the risk of metastasis among African American men.
A meta-analysis published in The Lancet Oncology reveals that men with intermediate- and high-risk prostate cancer experience improved overall survival with the addition of hormone therapy to radiotherapy. The study found prolonged adjuvant hormone therapy benefits men, while neoadjuvant hormone therapy did not.
A large international evaluation shows AI systems can identify and grade prostate cancer in tissue samples from different countries equally well as human pathologists. The results suggest AI can be a complementary tool in prostate cancer care, improving diagnostic quality and consistency.
Researchers aimed to tackle racial disparities in prostate cancer by targeting educational interventions to populations at highest risk. A study in Philadelphia neighborhoods found that prostate-specific education improved knowledge and intention to screen, with similar effects on control groups.
A UCI-led team identified a molecular feature in prostate cancer associated with ancestry, which may help predict patient risk and tailor treatment. ERV expression signatures also showed promise for identifying patients at greatest risk of progression across different ancestries.
The Society of Nuclear Medicine and Molecular Imaging has published appropriate use criteria (AUC) for prostate-specific membrane antigen (PSMA) PET imaging. The guidelines provide a framework for healthcare providers to determine the most effective use of PSMA PET scans in patients with suspected or known prostate cancer.
A portable prostate cancer screening kit could provide early warning to populations with higher incidence of prostate cancer, particularly African American men. The test uses a test strip and reader to quantify PSA from a drop of blood in minutes, delivering results in 10-15 minutes.
The study combined seven randomized clinical trials with 8,000 patients to compare overall and treatment-specific outcomes of Black and white men with localized prostate cancer who received radiation therapy. The results showed that there were significant racial disparities in response to radiation therapy for prostate cancer.
A meta-analysis of seven randomized trials found that Black men with localized prostate cancer had lower recurrence, metastasis, and mortality rates compared to white men. The study challenges the common belief that Black men with prostate cancer have a worse prognosis.
Researchers discover a chromatin degrader that blocks cancer-causing genes, offering potential treatment for over 90% of prostate cancers. The study found that blocking the SWI/SNF complex slowed cancer cell growth and induced cell death, especially in tumors driven by FOXA1 or androgen receptor.
Researchers have identified NDUFS1 and ATP5O as novel markers of aggressive prostate cancer, associated with poorer survival rates. The study's findings provide new insights into the disease's molecular mechanisms and potential targets for therapy.
A clinical study and register studies have failed to confirm previous findings that a medicine blocking testosterone could help against COVID-19. The researchers found no discernible signs of the drug having any beneficial effect on participants' health status.
Surgeons at Henry Ford Health performed the world's first precision prostatectomy through the bladder using a single port robotic surgical system. The procedure preserves a portion of the prostate capsule, improving functional outcomes such as erectile function and urinary control.
A study found that men with Li-Fraumeni syndrome have a 25-fold increased risk of developing aggressive prostate cancer, and those with inherited TP53 variants are diagnosed at a young age. Routine screening for prostate cancer is recommended for these individuals.
A team from the University of Washington has developed a non-destructive 3D imaging method that can help doctors more accurately diagnose borderline cases of prostate cancer. The new approach uses 3D images to identify complex features in tissue samples, which can increase the likelihood of correctly predicting a cancer's aggressiveness.
After the 2012 US Preventive Services Task Force (USPSTF) statement discouraging routine prostate-specific antigen (PSA) testing, rates of prostate cancer screening and biopsy decreased across racial groups. However, Black men had higher rates of local and metastatic prostate cancer despite similar screening rates.
A study at Tampere University in Finland found that statin users had lower rates of low-risk prostate cancers detected through screening, but no difference in high-risk cancer detection. Statin use also reduced prostate cancer mortality in screened men compared to unscreened men.
Researchers at Princeton University have discovered a new compound that can disable the MTDH gene, which is essential for cancer progression and metastasis. The compound shows promise in treating major human cancers, including breast, prostate, lung, and colon cancers.
Researchers found that dysregulation of enzymes in the glucuronidation pathway is associated with castration-resistant prostate cancer. The study suggests that reducing UGDH expression and/or activity can reverse castration resistance, potentially preventing or delaying therapeutic resistance.
Researchers have developed a new approach to studying prostate cancer, allowing them to track the behavior of individual cancer cells from birth to organ spread. The technique uses whole-organ imaging and artificial intelligence to create a 3D reconstruction of the organ at single-cell resolution.
Researchers produce large quantities of powerful cancer-fighting iNKT cells using stem cell engineering and organoid technology, offering a potential solution for mass-producing an off-the-shelf immune cell therapy. The therapy, which uses hematopoietic stem cell-engineered iNKT cells, has been shown to be effective in killing multiple...
A study of over 1,100 prostate cancer patients found that androgen deprivation therapy did not increase the risk of death within 30 days after a COVID-19 infection. Researchers concluded that men receiving androgen deprivation therapy had similar mortality rates as those who did not receive this treatment.
A new study in mice found that PFAS exposure reprograms the metabolism of benign and malignant human prostate cells to a more energy efficient state. Consuming a high-fat diet significantly accelerated development of tumors in PFAS-exposed mice, suggesting a synergistic interaction between the two.
Researchers developed a blood test that can detect prostate cancer patients who are resistant to chemotherapy drug docetaxel, enabling early detection and personalized treatment. The test analyzes circulating tumor cells in the bloodstream, revealing patterns that predict disease progression and survival.
A study analyzing 93 precision oncology studies revealed significant underrepresentation of racial and ethnic minority populations in cancer research. These disparities affect the representation of diverse patient groups in clinical trials, which can impact treatment efficacy and outcomes.
A recent study found that Black, Hispanic, and Asian men are less likely to receive an MRI exam after a prostate-specific antigen (PSA) blood test. The study suggests racial and ethnic disparities in the use of prostate MRIs following elevated PSA results.
Researchers found that restoring NXTAR expression can suppress prostate tumor growth, suggesting a new approach to treating hormone-resistant prostate cancer. The study identified an RNA molecule called NXTAR that plays a key role in regulating the androgen receptor, a protein driving prostate tumor growth.
A phase III clinical trial found that a trio of drugs, apalutamide, abiraterone, and prednisone, slowed the progression of metastatic castration-resistant prostate cancer by 24 months compared to 16.6 months with abiraterone and prednisone alone.
A new pilot study reveals a prostate cancer urine test can identify men with intermediate-risk disease, allowing them to opt for active surveillance instead of immediate treatment. The test assesses the amount of aggressive cancer in the prostate without needing a biopsy.
Researchers found diet-associated molecules in the gut are associated with aggressive prostate cancer, linking them to higher levels of metabolites like phenylacetylglutamine and nutrients choline and betaine. The study's findings may have clinical implications for diagnosing and preventing lethal prostate cancer.
A new international meta-analysis of randomized clinical trials found that adding androgen deprivation therapy (ADT) to definitive radiotherapy improves metastasis-free survival by 8% and overall survival by 7%. Prolonging adjuvant ADT for 18-36 months also shows similar benefits.
The NRG-RTOG 0815 trial found that adding androgen suppression to dose-escalated radiotherapy did not improve overall survival, but reduced rates of biochemical failure and distant metastases. Future studies are needed to identify subsets of patients who may benefit from this intervention.
A Phase III clinical trial found no significant increase in genitourinary or gastrointestinal toxicity with hypofractionated post-operative prostate bed radiotherapy compared to conventional radiotherapy. However, dose-escalated radiation therapy was not shown to be superior to conventional RT.
A recent clinical trial found that a shortened course of radiation therapy after prostate removal surgery does not increase long-term side effects or lower quality of life compared to conventional treatment. Patients who underwent hypofractionated, post-operative radiation therapy experienced comparable genitourinary and gastrointestin...
Scientists at Osaka University developed a novel system for targeted cancer radiation therapy using gold nanoparticles labeled with astatine-211. The nanoparticles are highly toxic to cancer cells while remaining localized, minimizing damage to healthy tissues.
Research suggests that regular PSA testing from age 40 could detect life-threatening prostate cancer in men with genetic hallmarks of Lynch syndrome, increasing the chances of earlier diagnosis and treatment. Men with MSH2 gene faults were eight times more likely to be diagnosed with prostate cancer at a younger age.
A new study found that common gut bacteria can drive prostate cancer growth and treatment resistance by providing an alternative source of growth-promoting androgens. Researchers identified specific bacterial 'fingerprints' linked to prostate cancer outcome, which could help identify men who could benefit from strategies to manipulate ...
The ARAMIS phase III clinical trial found that darolutamide improved metastasis-free survival and overall survival in Black/African American patients. Darolutamide-treated patients had a higher three-year overall survival rate and longer time to disease progression compared to placebo-treated patients.
A clinical trial found that obese prostate cancer patients who underwent regular exercise training for 12 weeks had increased levels of anti-cancer myokines, which suppressed tumour growth and helped fight cancerous cells. The study suggests exercise may be a key weapon in cancer patients' battle against the disease.
Researchers mapped cancer through protein interactions, revealing biomarkers and potential new treatments for breast and head and neck cancers. The study provides a new definition of biomarkers based on large, multi-protein complexes, offering a more precise way to explain mutation effects.
Researchers identified two subtypes of metastatic prostate cancer that respond differently to hormone treatment. Luminal tumors responded better to testosterone-blocking treatments, while basal tumors did not benefit as much from this hormone treatment.
Novartis presents Phase III MONALEESA-2 study results demonstrating improved overall survival with Kisqali (ribociclib) in combination with letrozole. The analysis shows a statistically significant and clinically meaningful improvement in survival, with median OS of 63.9 months.
A novel combination of abiraterone acetate and prednisolone has been shown to prolong survival in patients with hormone/castration-sensitive prostate cancer. Studies PEACE-1 and STAMPEDE found that the addition of these drugs to standard therapy lengthened survival compared to standard therapy alone.